[go: up one dir, main page]

MX2019003039A - Forma de dosificacion de alivio prolongado. - Google Patents

Forma de dosificacion de alivio prolongado.

Info

Publication number
MX2019003039A
MX2019003039A MX2019003039A MX2019003039A MX2019003039A MX 2019003039 A MX2019003039 A MX 2019003039A MX 2019003039 A MX2019003039 A MX 2019003039A MX 2019003039 A MX2019003039 A MX 2019003039A MX 2019003039 A MX2019003039 A MX 2019003039A
Authority
MX
Mexico
Prior art keywords
dosage form
pharmaceutically acceptable
acceptable salt
prolonged relief
dextromethorphan
Prior art date
Application number
MX2019003039A
Other languages
English (en)
Other versions
MX385881B (es
Inventor
Edward Stella Mark
Richard Entwisle John
BALAN Guhan
Ludher Baltej
E Clark Jonathan
Anness Daren
Nicholas Carr Andrew
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of MX2019003039A publication Critical patent/MX2019003039A/es
Publication of MX385881B publication Critical patent/MX385881B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una forma de dosificación con una primera porción y una segunda porción. La primera porción puede ser una porción de liberación inmediata y puede comprender un analgésico, que puede ser naproxeno o naproxeno sódico. La segunda porción puede ser una porción de liberación prolongada y puede comprender pseudoefedrina o una sal farmacéuticamente aceptable de esta y/o dextrometorfano o una sal farmacéuticamente aceptable de este. La forma de dosificación puede comprender, opcionalmente, un agente estabilizante. La forma de dosificación puede adaptarse para mantener una cantidad terapéuticamente eficaz de analgésico, pseudoefedrina, o una sal farmacéuticamente aceptable de esta, y/o dextrometorfano, o una sal farmacéuticamente aceptable de este, durante al menos ocho horas.
MX2019003039A 2016-09-26 2017-09-25 Forma de dosificacion de alivio prolongado MX385881B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662399511P 2016-09-26 2016-09-26
PCT/US2017/053157 WO2018058009A1 (en) 2016-09-26 2017-09-25 Extended relief dosage form

Publications (2)

Publication Number Publication Date
MX2019003039A true MX2019003039A (es) 2019-07-08
MX385881B MX385881B (es) 2025-03-18

Family

ID=60002143

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003039A MX385881B (es) 2016-09-26 2017-09-25 Forma de dosificacion de alivio prolongado

Country Status (10)

Country Link
US (2) US10576041B2 (es)
EP (1) EP3515413B1 (es)
CN (1) CN109789101A (es)
AU (1) AU2017331369B2 (es)
BR (1) BR112019005224A2 (es)
CA (1) CA3038263C (es)
MX (1) MX385881B (es)
PL (1) PL3515413T3 (es)
RU (1) RU2019109695A (es)
WO (1) WO2018058009A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201506755D0 (en) 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
CA3001337C (en) 2015-10-09 2023-12-12 Reckitt Benckiser Llc Pharmaceutical formulation
BR112019005224A2 (pt) 2016-09-26 2019-06-11 Procter & Gamble forma de dosagem para alívio prolongado
US11465426B2 (en) 2018-06-26 2022-10-11 Landa Corporation Ltd. Intermediate transfer member for a digital printing system
MX2023005639A (es) 2020-11-13 2023-09-22 Bayer Healthcare Llc Comprimidos de capa doble orales que comprenden acido acetilsalicilico y pseudoefedrina, metodos para preparar y utilizar los mismos.

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552899A (en) 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
EP0701434B1 (en) * 1993-06-04 2002-08-07 Warner-Lambert Company Preparations containing silicon dioxide to improve the taste thereof
JPH09502201A (ja) 1993-09-07 1997-03-04 ザ、プロクター、エンド、ギャンブル、カンパニー プロピオン酸非ステロイド系抗炎症剤のアミノ酸塩とうっ血除去剤、去痰剤、抗ヒスタミン剤及び鎮咳剤のうち少くとも１種を含有した組成物
US5859060A (en) 1997-01-15 1999-01-12 Platt; Chris Timed release tablet comprising naproxen and pseudoepherine
US6132758A (en) 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
EP1107740A4 (en) * 1998-08-25 2002-03-06 Platt Chris SLOW RELEASE TABLET COMPRISING NAPROXENE AND PSEUDOEPHEDRINE
SK287105B6 (sk) 1999-12-20 2009-12-07 Schering Corporation Dvojvrstvový orálny dávkový prostriedok s predĺženým uvoľňovaním
CN1596104A (zh) 2001-09-28 2005-03-16 麦克内尔-Ppc股份有限公司 改进的释放剂型
US6753009B2 (en) 2002-03-13 2004-06-22 Mcneil-Ppc, Inc. Soft tablet containing high molecular weight polyethylene oxide
CL2003002653A1 (es) 2002-12-18 2005-04-22 Wyeth Corp Composicion farmaceutica que comprende (a) un antiinflamatorio no esteroidal (nsaid), preferentemente ibuprofeno, (b) un descongestionante, preferentemente pseudoefedrina y (c) un antihistaminico, preferentemente clorfeniramina; metodo para su prepar
JP2007517776A (ja) * 2003-12-09 2007-07-05 スフェリックス， インコーポレイテッド カテコール官能基を有する生体接着性ポリマー
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US20050249802A1 (en) 2004-05-06 2005-11-10 The Procter & Gamble Company Softgel encapsulated pharmaceutical compositions comprising concentrated active ingredients
DE102004045037A1 (de) 2004-09-15 2006-03-16 Basf Ag Pharmazeutische Darreichungsformen mit erschwerter Extrahierbarkeit eines Sympathomimetikums aus der Darreichungsform
US20070003621A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Dosage forms for movement disorder treatment
WO2007072503A2 (en) 2005-12-21 2007-06-28 Panacea Biotec Ltd. Combinations for managing inflammation and associated disorders
WO2007141743A2 (en) * 2006-06-06 2007-12-13 Ranbaxy Laboratories Limited A tablet dosage form comprising cetirizine and pseudoephedrine
US20080014274A1 (en) 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
US9005652B2 (en) 2006-07-25 2015-04-14 Wyeth Chewable tablet containing phenylephrine
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
US9078824B2 (en) 2007-09-24 2015-07-14 The Procter & Gamble Company Composition and method of stabilized sensitive ingredient
US8162276B2 (en) 2008-09-29 2012-04-24 Clipsy, Llc Rotary joint assembly and combination clip-hook and jewelry piece employing the same
US8252330B2 (en) 2009-01-05 2012-08-28 Mcneil-Ppc, Inc. Tablet containing coated particles of cetirizine, pseudoephedrine, and/or naproxen
CA2748783A1 (en) 2009-01-05 2010-07-08 Mcneil-Ppc, Inc. Three layer tablet containing cetirizine, pseudoephedrine, and naproxen
MX357636B (es) * 2011-02-14 2018-07-17 Procter & Gamble Formas de dosificacion solidas que comprenden miel en el recubrimiento.
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
GB201506755D0 (en) * 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
CA3001337C (en) 2015-10-09 2023-12-12 Reckitt Benckiser Llc Pharmaceutical formulation
BR112019005224A2 (pt) 2016-09-26 2019-06-11 Procter & Gamble forma de dosagem para alívio prolongado

Also Published As

Publication number Publication date
PL3515413T3 (pl) 2023-11-13
WO2018058009A1 (en) 2018-03-29
RU2019109695A (ru) 2020-10-26
RU2019109695A3 (es) 2020-10-26
EP3515413A1 (en) 2019-07-31
US11433030B2 (en) 2022-09-06
CA3038263A1 (en) 2018-03-29
BR112019005224A2 (pt) 2019-06-11
US20180085317A1 (en) 2018-03-29
CN109789101A (zh) 2019-05-21
MX385881B (es) 2025-03-18
US20200113841A1 (en) 2020-04-16
AU2017331369B2 (en) 2019-11-21
EP3515413B1 (en) 2023-08-16
CA3038263C (en) 2022-04-05
US10576041B2 (en) 2020-03-03
AU2017331369A1 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
MX2019003039A (es) Forma de dosificacion de alivio prolongado.
DOP2016000298A (es) Pirazolopiridinas y pirazolopirimidinas
CU20170168A7 (es) Formulaciones farmacéuticas que comprenden tenofovir y emtricitabina
MX2022000143A (es) Metodos novedosos.
MX2020013116A (es) Sales y cristales novedosos.
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
PE20230735A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
CL2013001602A1 (es) Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple.
CL2011001621A1 (es) Composicion farmaceutica oral de liberacion sostenida que comprende en una forma de dosificacion unitaria, una matriz hidrofilica, un opioide, una sal de un aine, y opcionalmente un surfactante aniónico; y uso para preparar medicamentos utiles en la prevencion, alivio o disminución del nivel del dolor y supresión de la tos.
AR122580A2 (es) Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales
CL2012002317A1 (es) Compuestos derivados de tienopirimidinas, inhibitores de quinasas mnk1/mnk2; composicion farmaceutica; y su uso para elt ratamiento o profilaxis de enfermedades metabolicas, tales como diabetes, daño renal, cancer, enfermedades inflamatorias, entre otras.
CL2013000477A1 (es) Formulacion farmaceutica oral de liberacion inmediata que comprende nalbufina o una sal de la misma, y al menos, un soporte de granulacion hidrofilo, un aglutinante hidrofilo y un lubricante, util para el tratamiento del dolor y la dependencia a los opioides.
MX386808B (es) Sistema de suministro de fármaco que comprende un resto de hidrazona y un enlace amida para proporcionar liberción controlada de agentes terapéuticos
MX2016008429A (es) Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria.
CL2012002437A1 (es) Uso de antiinflamatorio no esteroide (aine) o una sal farmacologicamente aceptable del mismo para preparar un medicamento util para el tratamiento de enfermedades renales cronicas en gatos.
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
CL2008003006A1 (es) Uso de ester metilico del acido (-)-(3ar,4s,7ar)-4-hidroxi-4-m-toliletinil-octahidro-indol-1-carboxilico en base libre o en forma de sal para el tratamiento, prevencion o retraso de la progresion de la disquinesia de parkinson asociada a l-dopa; uso de la composicion farmaceutica; uso de una composicion que ademas comprende l-dopa.
DOP2016000003A (es) Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán
CL2012003341A1 (es) Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.
PE20151543A1 (es) Composicion farmaceutica oral de sales sulfato para comprimidos de uso dual y metodos para su uso
BR112015021480A2 (pt) soluções de hidromorfona intratecais tendo estabi-lidade melhorada
MX2013001279A (es) Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
MX2015012970A (es) Formas de dosificacion solidas de liberacion prolongada antiemeticas.
MX2021011795A (es) Composición farmaceutica que comprende esomeprazol 0 sal farmaceuticamente aceptable del mismo y que tiene un perfil de liberación doble.
CL2016002655A1 (es) Composición farmacéutica para el tratamiento de alopatías relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol